Amivantamab

💊Medication

Generic name

Amivantamab-Vmjw

Brand names

Rybrevant

Route

Intravenous

Type

Human Prescription Drug

Manufacturer

Janssen Biotech, Inc.

Indications: 1 INDICATIONS AND USAGE RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor r… (per FDA label)

• PHASE1/PHASE2ACTIVE_NOT_RECRUITING
  PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung CancerM.D. Anderson Cancer Center · NCT06083857
• PHASE2NOT_YET_RECRUITING
  Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)Yonsei University · NCT07507188
• PHASE2ACTIVE_NOT_RECRUITING
  Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKIETOP IBCSG Partners Foundation · NCT05601973
• PHASE2ACTIVE_NOT_RECRUITING
  Premedication to Reduce Amivantamab Associated Infusion Related ReactionsJanssen Research & Development, LLC · NCT05663866
• PHASE2ACTIVE_NOT_RECRUITING
  Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibJanssen Research & Development, LLC · NCT06120140
• PHASE1RECRUITING
  ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLCORIC Pharmaceuticals · NCT06816992

via ClinicalTrials.gov

Wikidata facts

Instance of

monoclonal antibody

via Wikidata · CC0